There is increasing interest concerning the use of natural
antioxidants as low toxic antileukemic compounds.
Antoksyd S (C/E/XXI), is a novel herbal
drug derived in Poland from the powdered roots of Scutellaria baicalensis, and the
biological activities of its major components (
baicalin and
baicalein) were compared on the human
leukemia cell line HL-60. On MTT assay,
Antoksyd S (C/E/XXI) showed an obvious cytotoxic effect on HL-60 cells, which was compared with those caused by
cisplatin and
doxorubicin under the same experimental conditions. A comparative assay of the antioxidative and prooxidative capacity of
Antoksyd S (C/E/XXI) was also undertaken using two different reactive species:
superoxide (O2-) and a transition
metal (Cu2+).
Antoksyd S (C/E/XXI) has low toxicity, acting as a modifier of HL-60 cells proliferation and as an
antioxidant, which could act prooxidatively in the presence of transition
metal ions. Taken together, it seems reasonable to suggest that
Antoksyd S (C/E/XXI) as compared to
baicalin and
baicalein, or to the
cytostatics cisplatin and
doxorubicin, might be an especially good candidate for the future development of new therapeutic techniques, alone or in "combination treatment regimens", to enhance
leukemia cell killing.